CAR-T-Cell Therapy: Present Progress and Future strategies

Chimeric antigen receptor (CAR) T-cell therapy is a type of immunotherapy that uses the patient's immune system. It creates cancer-killing T cells through genetic modification targets tumor antigens. CAR consists three fundamental units, extracellular, transmembrane, and intracellular domains. CARs are rapidly evolving with progress in field starting from first-generation to next-generation CARs. Different cancer types, including B-cell malignancies, being treated by CAR-T therapy. The FDA has approved two therapies, namely, tisagenlecleucel axicabtagene ciloleucel. recently products Lisocabtagene maraleucel Idecabtagene vicleucel. Despite success therapy, several limitations, cytokine release syndrome neurotoxicity, need be overcome. In present review, we have provided an overview generations, their applications, potential possible solutions for improving variety types.